Skip to main content
Figure 1 | Cardiovascular Diabetology

Figure 1

From: Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

Figure 1

Contractile properties of cardiomyocytes isolated from control, diabetic rats and diabetic rats treated with AZL (5 mg kg-1 day-1). A: Maximal velocity of shortening (+dL/dt, A) and relengthening (-dL/dt, B) of ventricular myocytes isolated from control, diabetic rats and diabetic rats treated with AZL (5 mg kg-1 day-1). B. Graph illustrates Peak shortening (PS, normalized to cell length) of the myocytes isolated from control, diabetic rats and diabetic rats treated with AZL. C. Graph illustrates time-to-peak shortening (TPS) of the myocytes isolated from control, diabetic rats and diabetic rats treated with AZL. D. Graph illustrates time-to-90% relengthening (TR90) of the myocytes isolated from control, diabetic rats and diabetic rats treated with AZL. Values are means ± SE; n = 151-163 cells from 5-7 rats per group, *P < 0.05 vs. control group; **P < 0.05 vs. diabetic group.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840